lotilaner oral (TP-05) / Tarsus Pharma - LARVOL DELTA

Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the treatment and control of Echinococcus multilocularis and E. granulosus infections in dogs. (PubMed, Parasit Vectors) - "Credelio Quattro administered once orally at the minimum dosages of 20 mg/kg of lotilaner, 0.02 mg/kg of moxidectin, 5.0 mg/kg of praziquantel and 5.0 mg/kg of pyrantel was safe and effective for the treatment and control of adult E. granulosus and E. multilocularis in dogs."

Journal • Infectious Disease

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: Tarsus Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Tarsus Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting | Phase classification: P2a ➔ P2

Enrollment closed • Phase classification

A Phase 1b Study of the Safety, Pharmacokinetics, and Ex Vivo Tick Killing of the Lyme Prophylaxis Candidate TP-05 (IDWeek 2023) - No abstract available

P1 data • PK/PD data • Preclinical • Infectious Disease

Study to Evaluate the Food Effect of TP-05 in Healthy Participants (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: Tarsus Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Sep 2023 ➔ May 2023

Trial completion • Trial completion date

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 (clinicaltrials.gov) - P2a | N=30 | Recruiting | Sponsor: Tarsus Pharmaceuticals, Inc. | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Nov 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date

Study to Evaluate the Food Effect of TP-05 in Healthy Participants (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: Tarsus Pharmaceuticals, Inc. | Trial completion date: Jun 2023 ➔ Sep 2023

Trial completion date

Study to Evaluate the Food Effect of TP-05 in Healthy Participants (clinicaltrials.gov) - P1 | N=42 | Active, not recruiting | Sponsor: Tarsus Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

Study to Evaluate the Food Effect of TP-05 in Healthy Participants (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Tarsus Pharmaceuticals, Inc.

New P1 trial

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 (clinicaltrials.gov) - P2a | N=30 | Recruiting | Sponsor: Tarsus Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2022 ➔ Dec 2023 | Initiation date: Jul 2022 ➔ Dec 2022 | Trial primary completion date: Nov 2022 ➔ Nov 2023

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date

A Pharmacokinetic Study of TP-05 in Healthy Subjects (clinicaltrials.gov) - P1 | N=67 | Completed | Sponsor: Tarsus Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 (clinicaltrials.gov) - P2a | N=30 | Not yet recruiting | Sponsor: Tarsus Pharmaceuticals, Inc.

New P2a trial